Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.73 USD
+0.04 (2.37%)
Updated Oct 15, 2024 03:46 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Biorestorative Therapies, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -14.42 | -18.49 | -44.30 | -11.27 | -14.65 |
Depreciation/Amortization & Depletion | 0.17 | 0.12 | 1.22 | 1.40 | 3.89 |
Net Change from Assets/Liabilities | 0.52 | 0.01 | 0.32 | 0.57 | 0.54 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.30 | 12.49 | 39.43 | 7.34 | 3.30 |
Net Cash From Operating Activities | -6.43 | -5.87 | -3.33 | -1.96 | -6.92 |
Property & Equipment | -0.17 | -0.27 | -0.03 | 0.00 | -0.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 3.42 | -13.04 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | -0.18 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 3.25 | -13.48 | -0.03 | 0.00 | -0.04 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.35 | 0.00 | 21.07 | 0.01 | 1.66 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.25 | 4.29 | 5.18 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.73 | 0.00 |
Net Cash from Financing Activities | 2.35 | 0.00 | 21.32 | 5.53 | 6.84 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.83 | -19.35 | 17.96 | 3.06 | -0.12 |
Cash at Beginning of Period | 1.71 | 21.03 | 3.06 | 0.00 | 0.12 |
Cash at End of Period | 0.89 | 1.68 | 21.03 | 3.06 | 0.00 |
Diluted Net EPS | -3.42 | -5.11 | -37.30 | -33.33 | -2,200.00 |
Fiscal Year End for Biorestorative Therapies, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -6.25 | -2.22 | -14.42 | -11.59 |
Depreciation/Amortization & Depletion | NA | 0.09 | 0.04 | 0.17 | 0.12 |
Net Change from Assets/Liabilities | NA | -0.28 | -0.48 | 0.52 | 0.39 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 2.26 | 0.34 | 7.30 | 6.42 |
Net Cash From Operating Activities | NA | -4.18 | -2.32 | -6.43 | -4.66 |
Property & Equipment | NA | -0.04 | 0.00 | -0.17 | 3.59 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -1.92 | -4.93 | 3.42 | -0.44 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -1.95 | -4.93 | 3.25 | 3.15 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 7.53 | 7.53 | 2.35 | 2.27 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.02 | -0.01 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 7.51 | 7.52 | 2.35 | 2.27 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 1.37 | 0.27 | -0.83 | 0.76 |
Cash at Beginning of Period | NA | 0.88 | 0.88 | 1.71 | 1.68 |
Cash at End of Period | NA | 2.25 | 1.16 | 0.89 | 2.44 |
Diluted Net EPS | NA | -0.50 | -0.33 | -0.48 | -0.64 |